This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Venous Thromboembolism  • Stroke  • Cardiovascular System  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

APASS Investigators

JAMA. 2004;291:576-584.

Context  The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial.

Objective  To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke.

Design, Setting, and Participants  The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory.

Main Outcome Measure  Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized).

Results  Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P = .94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P = .71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment x aPL interaction (P = .91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P = .07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event.

Conclusions  The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.

Authors: The APASS Writing Committee.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Antonio R. Cabral
JAMA. 2004;291(22):2701.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Guillermo Ruiz-Irastorza, Munther A. Khamashta, and Graham R. V. Hughes
JAMA. 2004;291(22):2701.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Denis Wahl, Véronique Regnault, Philippe de Moerloose, and Thomas Lecompte
JAMA. 2004;291(22):2701-2702.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events—Reply
Steven R. Levine, Robin L. Brey, Barbara C. Tilley, Douglas A. Triplett, J. L. P. Thompson, Ralph L. Sacco, J. P. Mohr, and for the APASS Investigators
JAMA. 2004;291(22):2702-2703.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial
James F. Toole, M. René Malinow, Lloyd E. Chambless, J. David Spence, L. Creed Pettigrew, Virginia J. Howard, Elizabeth G. Sides, Chin-Hua Wang, and Meir Stampfer
JAMA. 2004;291(5):565-575.
ABSTRACT | FULL TEXT  

The Challenge of Stroke Prevention
Daniel F. Hanley
JAMA. 2004;291(5):621-622.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How I treat the antiphospholipid syndrome
Giannakopoulos and Krilis
Blood 2009;114:2020-2030.
ABSTRACT | FULL TEXT  

Patent Foramen Ovale, Cardiac Valve Thickening, and Antiphospholipid Antibodies as Risk Factors for Subsequent Vascular Events: The PICSS-APASS Study
Rajamani et al.
Stroke 2009;40:2337-2342.
ABSTRACT | FULL TEXT  

Update of secondary stroke prevention
Diener and Weimar
Nephrol Dial Transplant 2009;24:1718-1724.
FULL TEXT  

How we diagnose the antiphospholipid syndrome
Giannakopoulos et al.
Blood 2009;113:985-994.
ABSTRACT | FULL TEXT  

Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry
Avcin et al.
Pediatrics 2008;122:e1100-e1107.
ABSTRACT | FULL TEXT  

Canadian Glaucoma Study: 2. Risk Factors for the Progression of Open-angle Glaucoma
Chauhan et al.
Arch Ophthalmol 2008;126:1030-1036.
ABSTRACT | FULL TEXT  

Finding Risks for Glaucoma
Brandt
Arch Ophthalmol 2008;126:1138-1139.
FULL TEXT  

New developments in lupus-associated antiphospholipid syndrome
Lockshin and Derksen
Lupus 2008;17:443-446.
ABSTRACT  

Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric sysemic lupus erythematosus
Katramados et al.
Lupus 2008;17:332-336.
ABSTRACT  

How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Garcia et al.
Blood 2007;110:3122-3127.
ABSTRACT | FULL TEXT  

The Antiphospholipid Syndrome
Rand
ASH Education Book 2007;2007:136-142.
ABSTRACT | FULL TEXT  

Treatment of Antiphospholipid Antibody Syndrome--Reply
Lim et al.
JAMA 2006;296:43-43.
FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Circulation 2006;113:e873-e923.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Stroke 2006;37:1583-1633.
ABSTRACT | FULL TEXT  

Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Circulation 2006;113:e409-e449.
ABSTRACT | FULL TEXT  

Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Bertolaccini and Khamashta
Lupus 2006;15:172-178.
ABSTRACT  

Management of Antiphospholipid Antibody Syndrome: A Systematic Review
Lim et al.
JAMA 2006;295:1050-1057.
ABSTRACT | FULL TEXT  

Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Stroke 2006;37:577-617.
ABSTRACT | FULL TEXT  

Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases
Shoenfeld et al.
Circulation 2005;112:3337-3347.
FULL TEXT  

Long-Term Therapy to Prevent Stroke
Kirshner et al.
J Am Board Fam Med 2005;18:528-540.
ABSTRACT | FULL TEXT  

Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation
Statkute et al.
Blood 2005;106:2700-2709.
ABSTRACT | FULL TEXT  

Stroke and antiphospholipid syndrome: the treatment debate
Ruiz-Irastorza and Khamashta
Rheumatology (Oxford) 2005;44:971-974.
ABSTRACT | FULL TEXT  

Thrombotic Risk Factors In Primary Antiphospholipid Syndrome: A 5-Year Prospective Study
Turiel et al.
Stroke 2005;36:1490-1494.
ABSTRACT | FULL TEXT  

Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
Chimowitz et al.
NEJM 2005;352:1305-1316.
ABSTRACT | FULL TEXT  

Thrombosis and the Antiphospholipid Syndrome
Ortel
ASH Education Book 2005;2005:462-468.
ABSTRACT | FULL TEXT  

Clinically Translated Ischemic Stroke Genomics
Meschia
Stroke 2004;35:2735-2739.
ABSTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Cabral
JAMA 2004;291:2701-2701.
FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Ruiz-Irastorza et al.
JAMA 2004;291:2701-2701.
FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Wahl et al.
JAMA 2004;291:2701-2702.
FULL TEXT  

Antiphospholipid Antibodies Do Not Predict Ischemic Stroke
JWatch General 2004;2004:3-3.
FULL TEXT  

The Challenge of Stroke Prevention
Hanley
JAMA 2004;291:621-622.
FULL TEXT